Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19

Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19

Background and Aims: Angiotensin-converting enzyme II (ACE2) is the key molecule for understanding the pathophysiology of COVID-19. The risk of COVID-19 and impact of immunosuppressive treatment on disease course in patients with inflammatory bowel disease (IBD) remain controversial. We aimed to det...

Full description

Bibliographic Details
Main Authors:	Xiao-Zhi Li, Yun Qiu, Louisa Jeffery, Fen Liu, Rui Feng, Jin-Shen He, Jin-Yu Tan, Zi-Yin Ye, Si-Nan Lin, Subrata Ghosh, Marietta Iacucci, Min-Hu Chen, Ren Mao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Medicine
Subjects:	COVID-19 ACE2 inflammatory bowel disease intestine anti-TNFα
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2020.613475/full

Similar Items

Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease
by: Marietta Iacucci, et al.
Published: (2011-03-01)

Diverse Immune Effects of Bovine Colostrum and Benefits in Human Health and Disease
by: Subrata Ghosh, et al.
Published: (2021-10-01)

Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?
by: Olga Maria Nardone, et al.
Published: (2019-07-01)

High definition i-SCAN endoscopy with water immersion technique accurately reflects histological severity of celiac disease
by: Marietta Iacucci, et al.
Published: (2016-05-01)

Ustekinumab for the treatment of Crohn’s disease: can it find its niche?
by: Ebby G. Simon, et al.
Published: (2016-01-01)

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy
by: Olga Maria Nardone, et al.
Published: (2023-04-01)

Tests that now deserve to be more widely adopted in IBD clinical practice
by: Nunzia Labarile, et al.
Published: (2020-07-01)

High-definition-iSCAN virtual chromoendoscopy has high sensitivity and specificity for the diagnosis of eosinophilic esophagitis
by: Eustace Gregory, et al.
Published: (2017-07-01)

Next-Generation Endoscopy in Inflammatory Bowel Disease
by: Irene Zammarchi, et al.
Published: (2023-07-01)

Technological advances in inflammatory bowel disease endoscopy and histology
by: Ludovico Alfarone, et al.
Published: (2022-11-01)

Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy
by: Marcin Sochal, et al.
Published: (2021-10-01)

Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study
by: Dimah AlAskar, et al.
Published: (2020-01-01)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
by: Javier P. Gisbert, et al.
Published: (2021-11-01)

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
by: Giorgia Colombo, et al.
Published: (2023-02-01)

Lack of Association between Tumor Necrosis Factor Alpha (TNFα) Gene -1031C/T Polymorphisms and Susceptibility to Inflammatory Bowel Disease (IBD)
by: Mahyar Nourian, et al.
Published: (2016-06-01)

Evaluation of TNF alpha G308A promoter gene polymorphism and serum TNF alpha levels in patients with inflammatory bowel disease in Turkish population
by: Resul Kahraman, et al.
Published: (2019-12-01)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
by: Sherman Picardo, et al.
Published: (2020-06-01)

Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
by: Sara Salvador-Martín, et al.
Published: (2024-04-01)

Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease.
by: Samuel C L Smith, et al.
Published: (2021-01-01)

Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn’s Disease
by: Yuhua Huang, et al.
Published: (2022-06-01)

The role of TNF-alpha gene (-238G/A and -308G/A) polymorphisms in the etiology and pathogenesis of inflammatory bowel diseases in various ethnic groups
by: I. V. Zhilin, et al.
Published: (2019-12-01)

A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model
by: Songmao Zheng, et al.
Published: (2020-01-01)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
by: Jihye Park, et al.
Published: (2022-09-01)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
by: Dan-in Jang, et al.
Published: (2021-03-01)

Systematic review of TNFα-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients
by: Rishab Revankar, et al.
Published: (2023-12-01)

Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
by: Ioana Ruxandra Mihai, et al.
Published: (2023-08-01)

Perturbation of the Human Microbiome as a Contributor to Inflammatory Bowel Disease
by: Bayan Missaghi, et al.
Published: (2014-06-01)

Oral TNF-α siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease
by: Geonhee Han, et al.
Published: (2024-04-01)

Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis
by: Laura Guberna, et al.
Published: (2021-05-01)

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study
by: Ivan Guerra, et al.
Published: (2023-01-01)

Clinical aspects and treatments for pediatric inflammatory bowel diseases
by: Jin Soo Moon
Published: (2019-01-01)

Genetically engineered Lactobacillus paracasei rescues colonic angiotensin converting enzyme 2 (ACE2) and attenuates hypertension in female Ace2 knock out rats
by: Xue Mei, et al.
Published: (2023-10-01)

Life-threatening bowel complications following anti-tumor necrosis factor antibody therapy for patients with inflammatory bowel disease: A report of three cases in Taiwan
by: Tzu-Chi Hsu, et al.
Published: (2022-01-01)

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
by: Dan Dou, et al.
Published: (2023-09-01)

How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions
by: Piotr Eder, et al.
Published: (2021-10-01)

Role of Angiotensin-Converting Enzyme (ACE) gene polymorphism and ACE activity in predicting outcome after acute myocardial infarction
by: Nagaraja Moorthy, et al.
Published: (2021-02-01)

No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study
by: Alaa El-Hussuna, et al.
Published: (2018-11-01)

ACE İnhibitörüne Bağlı Öksürük Senkopu
by: Ayşe KOÇ, et al.
Published: (2015-10-01)

Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice
by: Yan Chen, et al.
Published: (2021-07-01)

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
by: Guanglin Cui, et al.
Published: (2022-05-01)